Tuesday, August 16, 2016 9:49:08 AM
8K with shareholders letter:
https://www.sec.gov/Archives/edgar/data/1355848/000101968716007273/genius_8k-ex9901.htm
424B3 filing:
The 8K with the Llama Llama loan is attached at the bottom
https://www.sec.gov/Archives/edgar/data/1355848/000101968716007275/genius_424b3.htm
https://www.sec.gov/Archives/edgar/data/1355848/000101968716007275/0001019687-16-007275-index.htm
GENIUS BRANDS INTERNATIONAL, INC.
7,385,000 Shares of Common Stock
This Prospectus Supplement No. 2 supplements and amends the prospectus dated December 29, 2015, as amended and supplemented to date, relating to the public offering of up to 7,385,000 shares of common stock of Genius Brands International, Inc. by the selling stockholders, including 3,480,000 outstanding shares and 3,905,000 shares issuable upon exercise of outstanding warrants.
The selling stockholders may sell common stock from time to time in the principal market on which the common stock is traded at the prevailing market price or in negotiated transactions. We will not receive any of the proceeds from the sale of common stock by the selling stockholders.
This prospectus supplement incorporates into our prospectus the information contained in our attached:
· Current Report on Form 8-K, filed with the Securities and Exchange Commission on August 12, 2016; and
· Quarterly Report on Form 10-Q for the quarter ended June 30, 2016, filed with the Securities and Exchange Commission on August 15, 2016.
You should read this prospectus supplement in conjunction with the prospectus, including any supplements and amendments thereto. This prospectus supplement is qualified by reference to the prospectus except to the extent that the information in the prospectus supplement supersedes the information contained in the prospectus.
This prospectus supplement is not complete without, and may not be delivered or utilized except in connection with, the prospectus, including any supplements and amendments thereto.
Our common stock is quoted on the OTCQB and trades under the symbol “GNUS”. The last reported sale price of our common stock on the OTCQB on August 12, 2016, was $2.01 per share.
Investment in our common stock involves risks. See “Risk Factors” on page 5 of the prospectus, as updated or superseded by the “Risk Factors” section included in our Annual Report on Form 10-K for the fiscal year ended December 31, 2015.
Neither the Securities and Exchange Commission nor any state securities commission has passed upon the adequacy or accuracy of this prospectus supplement. Any representation to the contrary is a criminal offense.
The date of this prospectus supplement is August 15, 2016.
Recent GNUS News
- Form 8-K - Current report • Edgar (US Regulatory) • 04/19/2024 09:29:58 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 04/19/2024 09:29:26 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/16/2024 05:00:31 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/16/2024 01:05:11 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/11/2024 09:15:56 PM
- Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material • Edgar (US Regulatory) • 04/10/2024 08:10:20 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/09/2024 07:35:12 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 04/09/2024 12:05:33 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/09/2024 12:00:57 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 04/05/2024 09:15:03 PM
- Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 • Edgar (US Regulatory) • 04/01/2024 09:02:05 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/23/2024 01:27:15 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/23/2024 01:24:31 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/23/2024 01:23:08 AM
- Form 8-K/A - Current report: [Amend] • Edgar (US Regulatory) • 02/13/2024 10:28:41 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/30/2024 08:34:17 PM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 01/19/2024 09:30:21 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 01/19/2024 05:15:24 AM
- Form S-3/A - Registration statement under Securities Act of 1933: [Amend] • Edgar (US Regulatory) • 01/12/2024 09:50:35 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/09/2024 10:28:32 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/09/2024 06:35:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/09/2024 05:47:36 PM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 01/05/2024 10:09:06 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/03/2023 09:22:26 PM
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM